07.10.26 -- [VIDEO] GLP-1 Manufacturing's New Bottlenecks At Multi-Ton Scale

Translating EU GMP Annex 1 into consistent site-level practice is where most manufacturers struggle. Hear why the global-to-local execution gap remains the industry's biggest compliance challenge.

Dye ingress testing depends on pressure dynamics that shift with viscosity. Discover how these constraints narrow its operating window and call into question its reliability for high‑risk applications.

Three factors often decide success or failure in FIH studies: integrating biomarkers and pharmacodynamic endpoints, including patients in the trials, and leveraging purpose-built infrastructure.

ISO classification decisions shape cleanroom design. Learn how early alignment between process needs, biosafety, and classification can reduce redesign risk while supporting scalable environments.

Global partner delivering end‑to‑end drug development, manufacturing, and packaging with deep expertise, advanced facilities, and support across key modalities.

A two-day celebration in Dalian highlighted a major global investment milestone, featuring leadership perspectives, opening ceremonies, and the strategic vision behind expanded cGMP capabilities.

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

Chiral crystallization enables efficient production of enantiopure drug substances, improving pharmacological control and safety while supporting scalable small molecule development.

From early formulation challenges to scale-up and commercial readiness, proactive planning and integrated capabilities help teams anticipate risks, accelerate decision-making, and maintain momentum.

Explore a platform that optimizes high-concentration therapeutic antibody formulations, overcoming stability and manufacturability challenges to deliver safe, effective therapies.

Rushing early pharma development by neglecting quality and analytical frameworks risks regulatory failures, clinical holds, and expensive rework.